CDKN2A and meningioma: Despite there are very strong data supporting the prognostic importance of homozygous CDKN2A/B deletions in terms of meningioma progression, the impact of heterozygous CDKN2A/B deletions on progression-free survival (PFS) is not entirely clear so far.